Project Grant R01HD115560
Award Date 8/24/26
Completion Date 4/30/30
Dollars Obligated $3.6M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- The National Institutes of Health Office of the Director awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $371,250 under the Trans-NIH Research Support program (CFDA 93.310) on July 20, 2026, to develop and test the feasibility and acceptability of EASE-ENDO, an eight-session live video mind-body group intervention for endometriosis-associated pain. EASE-ENDO integrates evidence-based skills from Acceptance and Commitment Therapy and Dialectical...
- The National Institute of Neurological Disorders and Stroke awarded the University of Florida $187,317 on July 20, 2026, to characterize the endometriosis microbiome and metabolomic pain phenotype under the Drug Use and Addiction Research Programs (CFDA 93.279). The project stratifies individuals with endometriosis into treatment-responsive groups by identifying differences in microbial and NAD+ metabolomic patterns associated with differing pain characteristics, quality of life, psychological...
- The National Institute of Child Health and Human Development awarded Trustees of Tufts College $351,945 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate inflammation resolution mechanisms in endometrial health and disease. The research dissects how specialized pro-resolving mediators, a class of lipid-derived molecules that orchestrate inflammation resolution, operate in the human endometrium across the menstrual cycle. The...
- The National Institute of Neurological Disorders and Stroke awarded The McLean Hospital Corporation $468,368 on September 5, 2026, to investigate the relationship between gut microbiome composition, multisensory sensitivity, and pain experience in adolescent girls with primary dysmenorrhea under CFDA 93.279 (Drug Use and Addiction Research Programs). The project will evaluate how alterations in gut microbiome composition contribute to multisensory sensitivity—heightened sensitivity to...
- The National Institute of Child Health and Human Development awarded the University of Texas at Dallas $608,387 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate vaginal microbiome-nociceptor interactions in endometriosis pain. The research uses mouse models of endometriosis, intravaginal antibiotic treatment, vaginal microbiota transplant paradigms, and probiotic bacterial administration to explore the bidirectional...
- The National Institute of Neurological Disorders and Stroke awarded a Cooperative Agreement totaling $6.865 million to Seattle Children's Hospital (doing business as Seattle Children's Research Institute) on September 19, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279), with ultimate completion on July 31, 2030. The award funds development of a precision health model for pediatric chronic primary pain using the PEDSnet national pediatric learning health system...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Lowell $2.272 million on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to discover novel, non-opioid, non-addictive analgesics derived from marine microbial natural products. The award funds a phenotypic screening effort combining human induced pluripotent stem cell sensory neurons and glia cultured on multi-well microelectrode arrays to characterize sensory neuron...
- This $2,370,000 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop advanced human pluripotent stem cell (HPSC) tools to create comprehensive, region-specific models for studying pain circuitry. The award to Trustees of Tufts College (Tufts University) supports three main objectives: 1) Developing scalable methods to generate region-specific sensory neurons and...
- The National Institutes of Health Office of the Director awarded University of Massachusetts Medical School $479,385 on June 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate targeting platelet-derived growth factor receptor beta (PDGFR-beta) as a means to prevent opioid-induced respiratory depression and overdose deaths. The research combines behavioral pharmacology and neuroanatomical protein and mRNA expression mapping in the mouse brainstem to test the...